Mazdutide
Neutral, BioHarmony verdict
BioHarmony score 5.6 out of 10
Mazdutide (IBI362) is the first GLP-1 plus glucagon dual agonist approved anywhere, cleared in China for obesity in June 2025. Its Phase 3 GLORY-1 trial showed about 14.84 percent weight loss at 48 weeks and roughly 72 to 80 percent liver fat reduction, the strongest published incretin liver signal.
Read full reportWhat is Mazdutide?
Mazdutide, also called IBI362 or LY3305677, is the first GLP-1 plus glucagon dual agonist to win regulatory approval anywhere in the world. China's National Medical Products Administration cleared it for obesity in mid-2025 and for type 2 diabetes a few months later, sold there under the brand name Xinermei, per Lee 2025. It is a once-weekly subcutaneous injection. What sets it apart from semaglutide and tirzepatide is the second receptor: alongside the familiar GLP-1 leg that suppresses appetite, mazdutide also switches on the glucagon receptor, which raises energy expenditure and pushes the liver to burn its own fat.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Activates both the GLP-1 receptor and the glucagon receptor, the second leg adding energy expenditure and hepatic fat clearance
Safety watch-outs
- A persistent rise in resting heart rate, especially with palpitations: reduce the dose or stop and consult a clinician.
- Severe or unrelenting upper abdominal pain that may radiate to the back (possible pancreatitis): stop immediately and seek care.
- A neck lump, hoarseness, or trouble swallowing (the class thyroid warning): stop and get evaluated.
- Any active or suspected medullary thyroid cancer, or a family history of it: do not use.
- Signs of low blood sugar when combined with insulin or a sulfonylurea: stop the other drug or this one and consult a clinician.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Mazdutide yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Innovent reports that mazdutide is approved in China for chronic weight management; it is not FDA approved in the United States.
Primary sources
- Innovent mazdutide GLORY-2 update Innovent Biologics,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.